Editor’s Note
**Editor’s Note:** Hugel has announced its entry into India’s rapidly growing botulinum toxin market, targeting a 9% share this year. With a population of 1.5 billion and rising K-beauty interest, this move signals the company’s strategic expansion into a high-potential market.
Hugel (241,500 won ▲ 20,000, +9.03%) announced on the 22nd that it has entered the Indian botulinum toxin (Botox) market. India has a population of 1.5 billion, and interest in K-beauty is high among the middle class. Hugel aims to achieve a 9% market share in India this year.
Hugel recently participated in the Global Aesthetic Summit held in India, showcasing its Botox product “Letibo.” Botox is derived from toxic proteins extracted from Clostridium botulinum bacteria. When injected into the skin, it temporarily paralyzes muscles, smoothing out expression wrinkles.
Hugel, together with its local distributor Akamedical, will hold product events until the 24th. Academic exchanges and workshops are also being prepared. Hugel stated that it will accelerate its expansion into the Asia-Pacific region, using India as a base.
– Dong-A Socio HD absorbs Dong-A Pharmaceutical, transitioning to a business holding company.
– Food and Drug Safety Administration cracks down on 26 companies for false diet advertisements.
– KAIST develops ultra-precision measurement technology for battery electrode thickness.
* This article was translated using AI. Please send your feedback via this form.
View original article (Korean)
Hong Da-yeong Staff writer, Social News Desk